Autolus Therapeutics (AUTL) EBIT (2017 - 2026)

Autolus Therapeutics (AUTL) has 9 years of EBIT data on file, last reported at -$72.5 million in Q4 2025.

• Quarterly EBIT rose 4.48% year-over-year to -$72.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$270.5 million (down 12.06% YoY) and the FY2025 annual result came in at -$270.5 million, down 12.06% from the prior year.
• EBIT declined to -$72.5 million in Q4 2025, from -$71.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$11.6 million in Q4 2022 to a low of -$75.9 million in Q4 2024.
• A 5-year average of -$47.8 million and a median of -$41.6 million in 2021 frame the typical range for EBIT.
• Annual changes were most pronounced in 2021 — EBIT surged 51.19% — and 2023, when it slumped 357.26%.
• Tracing AUTL's EBIT over 5 years: stood at -$23.1 million in 2021, then jumped by 49.57% to -$11.6 million in 2022, then slumped by 357.26% to -$53.3 million in 2023, then sank by 42.41% to -$75.9 million in 2024, then increased by 4.48% to -$72.5 million in 2025.
• The last three EBIT figures came in at -$72.5 million (Q4 2025), -$71.6 million (Q3 2025), and -$61.2 million (Q2 2025), per Business Quant data.